Assigning site of origin in metastatic neuroendocrine neoplasms: A clinically significant application of diagnostic immunohistochemistry

Advances in Anatomic Pathology

Volumn 20, Issue 5, 2013, Pages 285-314

  Bellizzi, Andrew M ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

carcinoid tumor; carcinoma of unknown primary; CDX2; cytokeratin 20; immunohistochemistry; Merkel cell carcinoma; poorly differentiated neuroendocrine carcinoma; transcription factor; TTF 1; Well differentiated neuroendocrine tumor

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALPHA INTERFERON; ANTIGEN; CARBOPLATIN; CISPLATIN; CYTOKERATIN 20; CYTOKERATIN 7; ETOPOSIDE; EVEROLIMUS; INSULIN GENE ENHANCER BINDING PROTEIN ISL 1; MERKEL CELL POLYOMAVIRUS LARGE T ANTIGEN; OCTREOTIDE; PEPTIDE HORMONE; PROGESTERONE RECEPTOR; SECRETORY PROTEIN; SECRETORY PROTEIN 55; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 2A; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR PAX8; TRANSCRIPTION FACTOR PDX 1; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ABLATION THERAPY; ANATOMIC LANDMARK; ARTICLE; BIOLOGY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CANCER SURGERY; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM TUMOR; DRUG MECHANISM; ENDOSCOPIC SURGERY; EXCISION; GASTROINTESTINAL TUMOR; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MERKEL CELL TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; NEUROENDOCRINE TUMOR; NEUROFILAMENT; POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; WELL DIFFERENTIATED NEUROENDOCRINE TUMOR; WORLD HEALTH ORGANIZATION;

BIOPSY; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, UNKNOWN PRIMARY; NEUROENDOCRINE TUMORS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TERMINOLOGY AS TOPIC; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION;

EID: 84883410182     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3182a2dc67     Document Type: Article

References (264)

1. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplams of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. World Health Organization Classification of Tumours WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: IARC; 2010:13-14.
2. Travis WD. The concept of pulmonary neuroendocrine tumours. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. 3rd ed. Lyon: IARC Press; 2004:19-20.
3. Rekhtman N. Neuroendocrine tumors of the lung: An update. Arch Pathol Lab Med. 2010;134:1628-1638.
4. Pelosi G, Rodriguez J, Viale G, et al. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: A major pitfall in the management of lung cancer patients. Am J Surg Pathol. 2005;29:179-187.
5. Aslan DL, Gulbahce HE, Pambuccian SE, et al. Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact. Am J Clin Pathol. 2005;123:874-878.
6. Marx A, Shimosato Y, Kuo TT, et al. Thymic neuroendocrine tumours. In: Travis WD, Brambilla E, Muller- Hermelink HK, Harris CC, eds. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. 3rd ed. Lyon: IARC Press; 2004:188-195.
7. Matias-Guiu X, DeLellis R, Moley JF, et al. Medullary thyroid carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Endocrine Organs. 3rd ed. Lyon: IARC Press; 2004:86-91.
8. Williams ED, Sandler M. The classification of carcinoid tum ours. Lancet. 1963;1:238-239.
9. Soga J, Tazawa K. Pathologic analysis of carcinoids. Histologic reevaluation of 62 cases. Cancer. 1971;28:990-998.
10. Burke AP, Thomas RM, Elsayed AM, et al. Carcinoids of the jejunum and ileum: An immunohistochemical and clinicopathologic study of 167 cases. Cancer. 1997;79:1086-1093.
11. Burke AP, Sobin LH, Federspiel BH, et al. Appendiceal carcinoids: Correlation of histology and immunohistochemistry. Mod Pathol. 1989;2:630-637.
12. Iwafuchi M, Watanabe H, Ajioka Y, et al. Immunohistochemical and ultrastructural studies of twelve argentaffin and six argyrophil carcinoids of the appendix vermiformis. Hum Pathol. 1990;21:773-780.
13. Fiocca R, Rindi G, Capella C, et al. Glucagon, glicentin, proglucagon, PYY, PP and proPP-icosapeptide immunoreactivities of rectal carcinoid tumors and related non-tumor cells. Regul Pept. 1987;17:9-29.
14. Burke AP, Federspiel BH, Sobin LH, et al. Carcinoids of the duodenum. A histologic and immunohistochemical study of 65 tumors. Am J Surg Pathol. 1989;13:828-837.
15. Garbrecht N, Anlauf M, Schmitt A, et al. Somatostatinproducing neuroendocrine tumors of the duodenum and pancreas: Incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer. 2008;15:229-241.
16. Johnson LA, Lavin P, Moertel CG, et al. Carcinoids: The association of histologic growth pattern and survival. Cancer. 1983;51:882-889.
17. Yao JC, Hassan M, Phan A, et al. One hundred years after carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
18. Godwin JD II. Carcinoid tumors. An analysis of 2,837 cases. Cancer. 1975;36:560-569.
19. Modlin IM, Lye KD, Kidd MA. 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959.
20. Kirshbom PM, Kherani AR, Onaitis MW, et al. Carcinoids of unknown origin: Comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery. 1998;124: 1063-1070.
21. Pape UF, Berndt U, Muller-Nordhorn J, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008;15:1083-1097.
22. Lombard-Bohas C, Mitry E, O?Toole D, et al. Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology. 2009;89:217-222.
23. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21:1794-1803.
24. Catena L, Bichisao E, Milione M, et al. Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms? Tumori. 2011;97:564-567.
25. Wang SC, Parekh JR, Zuraek MB, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010;145:276-280.
26. Bomanji JB, Papathanasiou ND. (1)(1)(1)In-DTPA(0)- octreotide (Octreoscan), (1)(3)(1)I-MIBG and other agents for radionuclide therapy of NETs. Eur J Nucl Med Mol Imaging. 2012;39(suppl 1):S113-S125.
27. John M, Meyerhof W, Richter D, et al. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut. 1996;38:33-39.
28. Janson ET, Stridsberg M, Gobl A, et al. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res. 1998;58: 2375-2378.
29. Kimura N, Pilichowska M, Date F, et al. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res. 1999;5: 3483-3487.
30. Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 2002;440:461-475.
31. Ono K, Suzuki T, Miki Y, et al. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727. Anticancer Res. 2007;27(4B):2231-2239.
32. Zamora V, Cabanne A, Salanova R, et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liv Dis. 2010;42:220-225.
33. Sclafani F, Carnaghi C, Di Tommaso L, et al. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: Clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors. Tumori. 2011;97:620-628.
34. Schmid HA, Lambertini C, van Vugt HH, et al. Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: Development and immunohistochemical application in neuroendocrine tumors. Neuroendocrinology. 2012;95: 232-247.
35. Prasad V, Ambrosini V, Hommann M, et al. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010;37:67-77.
36. Krausz Y, Freedman N, Rubinstein R, et al. 68Ga-DOTANOC PET/CT imaging of neuroendocrine tumors: Comparison with (1)(1)(1)In-DTPA-octreotide (OctreoScan(R)). Mol Imaging Biol. 2011;13:583-593.
37. Savelli G, Lucignani G, Seregni E, et al. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero- pancreatic (GEP) neuroendocrine tumours. Nucl Med Commun. 2004;25:445-449.
38. Medicare physician fee schedule. 2013. Available at: Http://www.cms.gov/ apps/physician-fee-schedule/overview.aspx. Accessed April 7, 2013.
39. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg. 2003;197: 29-37.
40. Elias D, Lasser P, Ducreux M, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: A 15-year single center prospective study. Surgery. 2003;133:375-382.
41. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg. 2000;190:432-445.
42. Chen H, Hardacre JM, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival? J Am Coll Surg. 1998;187:88-92; discussion-3.
43. Maire F, Hammel P, Kianmanesh R, et al. Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery. 2009;145:69-75.
44. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663.
45. Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157-176.
46. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocindoxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519-523.
47. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117: 268-275.
48. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6- methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009;15:338-345.
49. Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23:4897-4904.
50. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364: 514-523.
51. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet. 2011;378:2005-2012.
52. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-513.
53. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403-3410.
54. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90:220-226.
55. Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416-2423.
56. Merkel cell carcinoma. 2012. Available at: Http://www.nccn.org/ professionals/physician-gls/pdf/mcc.pdf. Accessed February 5, 2013.
57. Moertel CG, Kvols LK, O?Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227-232.
58. Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39:799-800.
59. Neuroendocrine tumors. 2013. Available at: Http://www.nccn. org/professionals/physician-gls/pdf/neuroendocrine.pdf. Accessed April 30, 2013.
60. James R, Kazenwadel J. Homeobox gene expression in the intestinal epithelium of adult mice. J Biol Chem. 1991;266: 3246-3251.
61. Guo RJ, Suh ER, Lynch JP. The role of Cdx proteins in intestinal development and cancer. Cancer Biol Ther. 2004;3:593-601.
62. Silberg DG, Swain GP, Suh ER, et al. Cdx1 and cdx2 expression during intestinal development. Gastroenterology. 2000;119:961-971.
63. Moskaluk CA, Zhang H, Powell SM, et al. Cdx2 protein expression in normal and malignant human tissues: An immunohistochemical survey using tissue microarrays. Mod Pathol. 2003;16:913-919.
64. Bai YQ, Yamamoto H, Akiyama Y, et al. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett. 2002;176:47-55.
65. Phillips RW, Frierson HF Jr, Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol. 2003;27:1442-1447.
66. Gao N, White P, Kaestner KH. Establishment of intestinal identity and epithelial-mesenchymal signaling by Cdx2. Dev Cell. 2009;16:588-599.
67. Barbareschi M, Murer B, Colby TV, et al. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol. 2003;27: 141-149.
68. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: An immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303-310.
69. Borrisholt M, Nielsen S, Vyberg M. Demonstration of CDX2 is highly antibody dependant. Appl Immunohistochem Mol Morphol. 2013;21:64-72.
70. Koo J, Mertens RB, Mirocha JM, et al. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin. Mod Pathol. 2012;25:893-901.
71. Barbareschi M, Roldo C, Zamboni G, et al. CDX-2 homeobox gene product expression in neuroendocrine tumors: Its role as a marker of intestinal neuroendocrine tumors. Am J Surg Pathol. 2004;28:1169-1176.
72. Erickson LA, Papouchado B, Dimashkieh H, et al. Cdx2 as a marker for neuroendocrine tumors of unknown primary sites. Endocr Pathol. 2004;15:247-252.
73. La Rosa S, Rigoli E, Uccella S, et al. CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors. Virchows Arch. 2004;445:248-254.
74. Saqi A, Alexis D, Remotti F, et al. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol. 2005;123:394-404.
75. Jaffee IM, Rahmani M, Singhal MG, et al. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin. Arch Pathol Lab Med. 2006;130: 1522-1526.
76. Lin X, Saad RS, Luckasevic TM, et al. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol. 2007;15:407-414.
77. Schmitt AM, Riniker F, Anlauf M, et al. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol. 2008;32: 420-425.
78. Srivastava A, Hornick JL. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. Am J Surg Pathol. 2009;33:626-632.
79. Hermann G, Konukiewitz B, Schmitt A, et al. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: Expression of ISL1, PDX1, NGN3, and CDX2. Virchows Arch. 2011;459: 147-154.
80. Chan ES, Alexander J, Swanson PE, et al. PDX-1, CDX-2, TTF-1, and CK7: A reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms. Am J Surg Pathol. 2012;36:737-743.
81. Denby KS, Briones AJ, Bourne PA, et al. IMP3, NESP55, TTF-1 and CDX2 serve as an immunohistochemical panel in the distinction among small-cell carcinoma, gastrointestinal carcinoid, and pancreatic endocrine tumor metastasized to the liver. Appl Immunohistochem Mol Morphol. 2012;20: 573-579.
82. Graham RP, Shrestha B, Caron BL, et al. Islet-1 is a sensitive but not entirely specific marker for pancreatic neuroendocrine neoplasms and their metastases. Am J Surg Pathol. 2013; 37:399-405.
83. Rabban JT, Lerwill MF, McCluggage WG, et al. Primary ovarian carcinoid tumors may express CDX-2: A potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary. Int J Gynecol Pathol. 2009;28:41-48.
84. Civitareale D, Lonigro R, Sinclair AJ, et al. A thyroid-specific nuclear protein essential for tissue-specific expression of the thyroglobulin promoter. EMBO J. 1989;8:2537-2542.
85. Guazzi S, Price M, De Felice M, et al. Thyroid nuclear factor 1 (TTF-1) contains a homeodomain and displays a novel DNA binding specificity. EMBO J. 1990;9: 3631-3639.
86. Stanfel MN, Moses KA, Schwartz RJ, et al. Regulation of organ development by the NKX-homeodomain factors: An NKX code. Cell Mol Biol. 2005;suppl 51:OL785-OL799.
87. Lazzaro D, M Price, de Felice M, et al. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development. 1991;113:1093-1104.
88. Ikeda K, Clark JC, Shaw-White JR, et al. Gene structure and expression of human thyroid transcription factor-1 in respiratory epithelial cells. J Biol Chem. 1995;270:8108-8114.
89. Katoh R, Miyagi E, Nakamura N, et al. Expression of thyroid transcription factor-1 (TTF-1) in human C cells and medullary thyroid carcinomas. Hum Pathol. 2000;31: 386-393.
90. Kimura S, Hara Y, Pineau T, et al. The T/ebp null mouse: Thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev. 1996;10:60-69.
91. Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol. 1996;9:445-452.
92. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000;36:8-16.
93. Katoh R, Kawaoi A, Miyagi E, et al. Thyroid transcription factor-1 in normal, hyperplastic, and neoplastic follicular thyroid cells examined by immunohistochemistry and nonradioactive in situ hybridization. Mod Pathol. 2000;13: 570-576.
94. Bejarano PA, Nikiforov YE, Swenson ES, et al. Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. Appl Immunohistochem Mol Morphol. 2000;8:189-194.
95. Ordó n? ez NG. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Adv Anat Pathol. 2000;7: 123-127.
96. Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000;36:415-420.
97. Oliveira AM, Tazelaar HD, Myers JL, et al. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol. 2001;25:815-819.
98. Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000;13:238-242.
99. Hirsch MS, Faquin WC, Krane JF. Thyroid transcription factor-1, but not p53, is helpful in distinguishing moderately differentiated neuroendocrine carcinoma of the larynx from medullary carcinoma of the thyroid. Mod Pathol. 2004;17:631-636.
100. Holzinger A, Dingle S, Bejarano PA, et al. Monoclonal antibody to thyroid transcription factor-1: Production, characterization, and usefulness in tumor diagnosis. Hybridoma. 1996;15:49-53.
101. Compérat E, Zhang F, Perrotin C, et al. Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin. Mod Pathol. 2005;18: 1371-1376.
102. Matoso A, Singh K, Jacob R, et al. Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol. 2010;18:142-149.
103. Fabbro D, Di Loreto C, Stamerra O, et al. TTF-1 gene expression in human lung tumours. Eur J Cancer. 1996;32A: 512-517.
104. Folpe AL, Gown AM, Lamps LW, et al. Thyroid transcription factor-1: Immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol. 1999;12:5-8.
105. Cai YC, Banner B, Glickman J, et al. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. Hum Pathol. 2001;32:1087-1093.
106. Sturm N, Rossi G, Lantuejoul S, et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol. 2002;33:175-182.
107. Zamecnik J, Kodet R. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: A study of 109 cases. Virchows Arch. 2002;440:353-361.
108. Chang YL, Lee YC, LiaoWY, et al. The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. Lung Cancer. 2004;44:149-157.
109. Du EZ, Goldstraw P, Zacharias J, et al. TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location. Hum Pathol. 2004;35:825-831.
110. Jerome Marson V, Mazieres J, Groussard O, et al. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: Correlation with histological type and grade. Histopathology. 2004;45:125-134.
111. Hiroshima K, Iyoda A, Shida T, et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: A morphological, immunohistochemical, and molecular analysis. Mod Pathol. 2006;19:1358-1368.
112. La Rosa S, Chiaravalli AM, Placidi C, et al. TTF1 expression in normal lung neuroendocrine cells and related tumors: Immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch. 2010;457:497-507.
113. Tsuta K, Kalhor N, Wistuba II, et al. Clinicopathological and immunohistochemical analysis of spindle-cell carcinoid tumour of the lung. Histopathology. 2011;59:526-536.
114. Masai K, Tsuta K, Kawago M, et al. Expression of squamous cell carcinoma markers and adenocarcinoma markers in primary pulmonary neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol. 2013;21:292-297.
115. Macchia PE, Lapi P, Krude H, et al. PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat Genet. 1998;19:83-86.
116. Mansouri A, Chowdhury K, Gruss P. Follicular cells of the thyroid gland require Pax8 gene function. Nat Genet. 1998;19:87-90.
117. Plachov D, Chowdhury K, Walther C, et al. Pax8 a murine paired box gene expressed in the developing excretory system and thyroid gland. Development. 1990;110:643-651.
118. Bouchard M, Souabni A, Mandler M, et al. Nephric lineage specification by Pax2 and Pax8. Genes Dev. 2002;16: 2958-2970.
119. Schaner ME, Ross DT, Ciaravino G, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell. 2003;14: 4376-4386.
120. Nonaka D, Tang Y, Chiriboga L, et al. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol. 2008; 21:192-200.
121. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32:1566-1571.
122. Tong GX, Yu WM, Beaubier NT, et al. Expression of PAX8 in normal and neoplastic renal tissues: An immunohistochemical study. Mod Pathol. 2009;22:1218-1227.
123. Long KB, Srivastava A, Hirsch MS, et al. PAX8 Expression in well-differentiated pancreatic endocrine tumors: Correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol. 2010;34:723-729.
124. Sangoi AR, Ohgami RS, Pai RK, et al. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol. 2011;24:412-424.
125. Ozcan A, Shen SS, Hamilton C, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: A comprehensive immunohistochemical study. Mod Pathol. 2011;24:751-764.
126. Haynes CM, Sangoi AR, Pai RK. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens. Cancer Cytopathol. 2011;119:193-201.
127. Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35:816-826.
128. Tacha D, Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic tissues: A comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol. 2011;19:293-299.
129. Lorenzo PI, Jimenez Moreno CM, Delgado I, et al. Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors. Histochem Cell Biol. 2011;136:595-607.
130. Tacha D, Qi W, Zhou D, et al. PAX8 mouse monoclonal antibody [BC12] recognizes a restricted epitope and is highly sensitive in renal cell and ovarian cancers but does not crossreact with b cells and tumors of pancreatic origin. Appl Immunohistochem Mol Morphol. 2013;21:59-63.
131. Agaimy A, Erlenbach-Wunsch K, Konukiewitz B, et al. ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin. Mod Pathol. 2013;26:995-1003.
132. Fendrich V, Ramerth R, Waldmann J, et al. Sonic hedgehog and pancreatic-duodenal homeobox 1 expression distinguish between duodenal and pancreatic gastrinomas. Endocr Relat Cancer. 2009;16:613-622.
133. Zhang L, Smyrk TC, Oliveira AM, et al. KIT is an independent prognostic marker for pancreatic endocrine tumors: A finding derived from analysis of islet cell differentiation markers. Am J Surg Pathol. 2009;33:1562-1569.
134. Park JY, Hong SM, Klimstra DS, et al. Pdx1 expression in pancreatic precursor lesions and neoplasms. Appl Immunohistochem Mol Morphol. 2011;19:444-449.
135. Jeung JA, Cao D, Selli BW, et al. Primary renal carcinoid tumors: Clinicopathologic features of 9 cases with emphasis on novel immunohistochemical findings. Hum Pathol. 2011;42: 1554-1561.
136. Sosa-Pineda B, Chowdhury K, Torres M, et al. The Pax4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. Nature. 1997;386:399-402.
137. St-Onge L, Sosa-Pineda B, Chowdhury K, et al. Pax6 is required for differentiation of glucagon-producing alpha-cells in mouse pancreas. Nature. 1997;387:406-409.
138. Sander M, Neubuser A, Kalamaras J, et al. Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. Genes Dev. 1997;11:1662-1673.
139. Moreno CM, Lorenzo PI, Delgado I, et al. Pax8 detection in well-differentiated pancreatic endocrine tumors: How reliable is it? Am J Surg Pathol. 2011;35:1906-1908.
140. Karlsson O, Thor S, Norberg T, et al. Insulin gene enhancer binding protein Isl-1 is a member of a novel class of proteins containing both a homeo- and a Cys-His domain. Nature. 1990;344:879-882.
141. Thor S, Ericson J, Brannstrom T, et al. The homeodomain LIM protein Isl-1 is expressed in subsets of neurons and endocrine cells in the adult rat. Neuron. 1991;7:881-889.
142. Ahlgren U, Pfaff SL, Jessell TM, et al. Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. Nature. 1997;385:257-260.
143. Di Loreto C, Di Lauro V, Puglisi F, et al. Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. J Clin Pathol. 1997;50:30-32.
144. Byrd-Gloster AL, Khoor A, Glass LF, et al. Differential expression of thyroid transcription factor 1 in small cell lung carcinoma and Merkel cell tumor. Hum Pathol. 2000;31:58-62.
145. Hanly AJ, Elgart GW, Jorda M, et al. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates merkel cell carcinoma from small cell carcinoma of lung. J Cutan Pathol. 2000;27:118-120.
146. Ordónez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol. 2000;24:1217-1223.
147. Cheuk W, Kwan MY, Suster S, et al. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med. 2001;125:228-231.
148. Shin SJ, DeLellis RA, Rosen PP. Small cell carcinoma of the breast-additional immunohistochemical studies. Am J Surg Pathol. 2001;25:831-832.
149. Leech SN, Kolar AJ, Barrett PD, et al. Merkel cell carcinoma can be distinguished from metastatic small cell carcinoma using antibodies to cytokeratin 20 and thyroid transcription factor 1. J Clin Pathol. 2001;54:727-729.
150. Sturm N, Lantuejoul S, Laverriere MH, et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol. 2001;32:918-925.
151. Chhieng DC, Cangiarella JF, Zakowski MF, et al. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer. 2001;93:330-336.
152. Wu M, Wang B, Gil J, et al. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol. 2003;119:696-702.
153. Myong NH. Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: Its prognostic implication and relationship with wxpressions of p53 and Ki-67 proteins. J Korean Med Sci. 2003;18:494-500.
154. Yamamoto J, Ohshima K, Ikeda S, et al. Primary esophageal small cell carcinoma with concomitant invasive squamous cell carcinoma or carcinoma in situ. Hum Pathol. 2003;34: 1108-1115.
155. Yang DT, Holden JA, Florell SR. CD117, CK20, TTF-1, and DNA topoisomerase II-alpha antigen expression in small cell tumors. J Cutan Pathol. 2004;31:254-261.
156. Liu J, Farhood A. Immunostaining for thyroid transcription factor-1 on fine-needle aspiration specimens of lung tumors: A comparison of direct smears and cell block preparations. Cancer. 2004;102:109-114.
157. Nagao T, Gaffey TA, Olsen KD, et al. Small cell carcinoma of the major salivary glands: Clinicopathologic study with emphasis on cytokeratin 20 immunoreactivity and clinical outcome. Am J Surg Pathol. 2004;28:762-770.
158. Soriano P, Navarro S, Gil M, et al. Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases. Virchows Arch. 2004;445:292-297.
159. McCluggage WG, Oliva E, Connolly LE, et al. An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcemic type. Int J Gynecol Pathol. 2004;23:330-336.
160. Liu J, Farhood A. Thyroid transcription factor-1 immunocytochemical staining of pleural fluid cytocentrifuge preparations for detection of small cell lung carcinoma. Acta Cytol. 2004;48:635-640.
161. Zhang H, Liu J, Cagle PT, et al. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: An immunohistochemical approach. Mod Pathol. 2005;18:111-118.
162. Nassar H, Albores-Saavedra J, Klimstra DS. High-grade neuroendocrine carcinoma of the ampulla of vater: A clinicopathologic and immunohistochemical
163. Llombart B, Monteagudo C, Lopez-Guerrero JA, et al. Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers. Histopathology. 2005;46:622-634.
164. Jones TD, Kernek KM, Yang XJ, et al. Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: An immunohistochemical profile of 44 cases. Hum Pathol. 2005;36:718-723.
165. Wu M, Szporn AH, Zhang D, et al. Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers. Diagn Cytopathol. 2005;33:223-227.
166. Bobos M, Hytiroglou P, Kostopoulos I, et al. Immunohistochemical distinction between merkel cell carcinoma and small cell carcinoma of the lung. Am J Dermatopathol. 2006;28:99-104.
167. Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: An immunohistochemical study. Am J Surg Pathol. 2006;30:705-712.
168. Kalhor N, Zander DS, Liu J. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material. Mod Pathol. 2006;19:1117-1123.
169. Yun JP, Zhang MF, Hou JH, et al. Primary small cell carcinoma of the esophagus: Clinicopathological and immunohistochemical features of 21 cases. BMC Cancer. 2007;7:38.
170. Carlson JW, Nucci MR, Brodsky J, et al. Biomarker-assisted diagnosis of ovarian, cervical and pulmonary small cell carcinomas: The role of TTF-1, WT-1 and HPV analysis. Histopathology. 2007;51:305-312.
171. El Demellawy D, Khalifa MA, Ismiil N, et al. Primary colorectal small cell carcinoma: A clinicopathological and immunohistochemical study of 10 cases. Diagn Pathol. 2007;2:35.
172. Alijo Serrano F, Sanchez-Mora N, Angel Arranz J, et al. Large cell and small cell neuroendocrine bladder carcinoma: Immunohistochemical and outcome study in a single institution. Am J Clin Pathol. 2007;128:733-739.
173. Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol. 2007;15: 415-420.
174. Lu J, Xue LY, Lu N, et al. Superficial primary small cell carcinoma of the esophagus: Clinicopathological and immunohistochemical analysis of 15 cases. Dis Esophagus. 2010;23:153-159.
175. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008;32:65-71.
176. Ralston J, Chiriboga L, Nonaka D. MASH1: A useful marker in differentiating pulmonary small cell carcinoma from Merkel cell carcinoma. Mod Pathol. 2008;21:1357-1362.
177. McCluggage WG, Kennedy K, Busam KJ. An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63. Am J Surg Pathol. 2010;34:525-532.
178. Li AF, Li AC, Hsu CY, et al. Small cell carcinomas in gastrointestinal tract: Immunohistochemical and clinicopathological features. J Clin Pathol. 2010;63:620-625.
179. Lewis JS Jr, Duncavage E, Klonowski PW. Oral cavity neuroendocrine carcinoma: A comparison study with cutaneous Merkel cell carcinoma and other mucosal head and neck neuroendocrine carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:209-217.
180. Sidiropoulos M, Hanna W, Raphael SJ, et al. Expression of TdT in Merkel cell carcinoma and small cell lung carcinoma. Am J Clin Pathol. 2011;135:831-838.
181. Fernández-Acen? ero MJ, Cordova S, Manzarbeitia F, et al. Immunohistochemical profile of urothelial and small cell carcinomas of the bladder. Pathol Oncol Res. 2011;17:519-523.
182. Thompson S, Cioffi-Lavina M, Chapman-Fredricks J, et al. Distinction of high-grade neuroendocrine carcinoma/small cell carcinoma from conventional urothelial carcinoma of urinary bladder: An immunohistochemical approach. Appl Immunohistochem Mol Morphol. 2011;19:395-399.
183. Quinn AM, Blackhall F, Wilson G, et al. Extrapulmonary small cell carcinoma: A clinicopathological study with identification of potential diagnostic mimics. Histopathology. 2012;61:454-464.
184. Moll R, Lowe A, Laufer J, et al. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol. 1992;140:427-447.
185. Brinkschmidt C, Stolze P, Fahrenkamp AG, et al. Immunohistochemical demonstration of chromogranin A, chromogranin B, and secretoneurin in Merkel cell carcinoma of the skin: An immunohistochemical study on 18 cases suggesting two types of Merkel cell carcinoma. Appl Immunohistochem. 1995;3:37-44.
186. Wang NP, Zee S, Zarbo RJ, et al. Coordinate expression of cytokeratins 7 and 20 defined unique subsets of carcinomas. Appl Immunohistochem. 1995;3:99-107.
187. Miettinen M. Keratin 20: Immunohistochemical marker for gastrointestinal, urothelial, and Merkel cell carcinomas. Mod Pathol. 1995;8:384-388.
188. Chan JK, Suster S, Wenig BM, et al. Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. Am J Surg Pathol. 1997;21:226-234.
189. Schmidt U, Muller U, Metz KA, et al. Cytokeratin and neurofilament protein staining in Merkel cell carcinoma of the small cell type and small cell carcinoma of the lung. Am J Dermatopathol. 1998;20:346-351.
190. Metz KA, Jacob M, Schmidt U, et al. Merkel cell carcinoma of the eyelid: Histological and immunohistochemical features with special respect to differential diagnosis. Graefes Arch Clin Exp Ophthalmol. 1998;236:561-566.
191. Scott MP, Helm KF. Cytokeratin 20: A marker for diagnosing Merkel cell carcinoma. Am J Dermatopathol. 1999;21:16-20.
192. Nicholson SA, McDermott MB, Swanson PE, et al. CD99 and cytokeratin-20 in small-cell and basaloid tumors of the skin. Appl ImmunohistochemMol Morphol. 2000;8:37-41.
193. Shin SJ, DeLellis RA, Ying L, et al. Small cell carcinoma of the breast: A clinicopathologic and immunohistochemical study of nine patients. Am J Surg Pathol. 2000;24:1231-1238.
194. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases. Mod Pathol. 2000;13:962-972.
195. Jensen K, Kohler S, Rouse RV. Cytokeratin staining in Merkel cell carcinoma: An immunohistochemical study of cytokeratins 5/6, 7, 17.Appl Immunohistochem Mol Morphol. 2000;8:310-315.
196. Kende AI, Carr NJ, Sobin LH. Expression of cytokeratins 7 and 20 in carcinomas of the gastrointestinal tract. Histopathology. 2003;42:137-140.
197. Mott RT, Smoller BR, Morgan MB. Merkel cell carcinoma: A clinicopathologic study with prognostic implications. J Cutan Pathol. 2004;31:217-223.
198. Tanaka Y, Sano T, Qian ZR, et al. Expression of adhesion molecules and cytokeratin 20 in merkel cell carcinomas. Endocr Pathol. 2004;15:117-129.
199. Ishida GM, Kato N, Hayasaka T, et al. Small cell neuroendocrine carcinomas of the uterine cervix: A histological, immunohistochemical, and molecular genetic study. Int J Gynecol Pathol. 2004;23:366-372.
200. Acebo E, Vidaurrazaga N, Varas C, et al. Merkel cell carcinoma: A clinicopathological study of 11 cases. J Eur Acad Dermatol Venereol. 2005;19:546-551.
201. Saeb-Lima M, Montante-Montes de Oca D, Albores-Saavedra J. Merkel cell carcinoma with eccrine differentiation: A clinicopathologic study of 7 cases. Ann Diagn Pathol. 2008;12:410-414.
202. Chernock RD, Duncavage EJ, Gnepp DR, et al. Absence of Merkel cell polyomavirus in primary parotid high-grade neuroendocrine carcinomas regardless of cytokeratin 20 immunophenotype. Am J Surg Pathol. 2011;35:1806-1811.
203. Moll R, Franke WW. Cytoskeletal differences between human neuroendocrine tumors: A cytoskeletal protein of molecular weight 46,000 distinguishes cutaneous from pulmonary neuroendocrine neoplasms. Differentiation. 1985;30:165-175.
204. Moll R, Franke WW, Schiller DL, et al. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11-24.
205. Moll R, Schiller DL, Franke WW. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol. 1990;111:567-580.
206. Broers JL, Ramaekers FC, Rot MK, et al. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res. 1988;48: 3221-3229.
207. Alsaad KO, Serra S, Schmitt A, et al. Cytokeratins 7 and 20 immunoexpression profile in goblet cell and classical carcinoids of appendix. Endocr Pathol. 2007;18:16-22.
208. Jiang Y, Long H, Wang W, et al. Clinicopathological features and immunoexpression profiles of goblet cell carcinoid and typical carcinoid of the appendix. Pathol Oncol Res. 2011;17:127-132.
209. Ischia R, Lovisetti-Scamihorn P, Hogue-Angeletti R, et al. Molecular cloning and characterization of NESP55, a novel chromogranin-like precursor of a peptide with 5-HT1B receptor antagonist activity. J Biol Chem. 1997;272:11657-11662.
210. Jakobsen AM, Ahlman H, Kolby L, et al. NESP55, a novel chromogranin-like peptide, is expressed in endocrine tumours of the pancreas and adrenal medulla but not in ileal carcinoids. Br J Cancer. 2003;88:1746-1754.
211. Srivastava A, Padilla O, Fischer-Colbrie R, et al. Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids. Am J Surg Pathol. 2004;28:1371-1378.
212. Ohlsson H, Karlsson K, Edlund T. IPF1 a homeodomaincontaining transactivator of the insulin gene. EMBO J. 1993; 12:4251-4259.
213. Leonard J, Peers B, Johnson T, et al. Characterization of somatostatin transactivating factor-1, a novel homeobox factor that stimulates somatostatin expression in pancreatic islet cells. Mol Endocrinol. 1993;7:1275-1283.
214. Offield MF, Jetton TL, Labosky PA, et al. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development. 1996;122:983-995.
215. Jonsson J, Carlsson L, Edlund T, et al. Insulin-promoterfactor 1 is required for pancreas development in mice. Nature. 1994;371:606-609.
216. Wilander E, Grimelius L, Portela-Gomes G, et al. Substance P and enteroglucagon-like immunoreactivity in argentaffin and argyrophil midgut carcinoid tumours. Scand J Gastroenterol Suppl. 1979;53:19-25.
217. Alumets J, Alm P, Falkmer S, et al. Immunohistochemical evidence of peptide hormones in endocrine tumors of the rectum. Cancer. 1981;48:2409-2415.
218. O?Briain DS, Dayal Y, DeLellis RA, et al. Rectal carcinoids as tumors of the hindgut endocrine cells: A morphological and immunohistochemical analysis. Am J Surg Pathol. 1982;6: 131-142.
219. Yang K, Ulich T, Cheng L, et al. The neuroendocrine products of intestinal carcinoids. An immunoperoxidase study of 35 carcinoid tumors stained for serotonin and eight polypeptide hormones. Cancer. 1983;51:1918-1926.
220. Shimoda T, Ishikawa E, Sano T, et al. Histopathological and immunohistochemical study of neuroendocrine tumors of the rectum. Acta Pathol Jpn. 1984;34:1059-1077.
221. Warren WH, Memoli VA, Gould VE. Immunohistochemical and ultrastructural analysis of bronchopulmonary neuroendocrine neoplasms. I. Carcinoids. Ultrastruct Pathol. 1984;6:15-27.
222. Federspiel BH, Burke AP, Sobin LH, et al. Rectal and colonic carcinoids. A clinicopathologic study of 84 cases. Cancer. 1990;65:135-140.
223. Doglioni C, Gambacorta M, Zamboni G, et al. Immunocytochemical localization of progesterone receptors in endocrine cells of the human pancreas. Am J Pathol. 1990;137:999-1005.
224. Viale G, Doglioni C, Gambacorta M, et al. Progesterone receptor immunoreactivity in pancreatic endocrine tumors. An immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. Cancer. 1992;70:2268-2277.
225. Zhao C, Bratthauer GL, Barner R, et al. Comparative analysis of alternative and traditional immunohistochemical markers for the distinction of ovarian sertoli cell tumor from endometrioid tumors and carcinoid tumor: A study of 160 cases. Am J Surg Pathol. 2007;31:255-266.
226. Sica G, Wagner PL, Altorki N, et al. Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors. Arch Pathol Lab Med. 2008;132:1889-1895.
227. Sobin LH, Hjermstad BM, Sesterhenn IA, et al. Prostatic acid phosphatase activity in carcinoid tumors. Cancer. 1986;58: 136-138.
228. Azumi N, Traweek ST, Battifora H. Prostatic acid phosphatase in carcinoid tumors. Immunohistochemical and immunoblot studies. Am J Surg Pathol. 1991;15:785-790.
229. Choe BK, Pontes EJ, Rose NR, et al. Expression of human prostatic acid phosphatase in a pancreatic islet cell carcinoma. Invest Urol. 1978;15:312-318.
230. Jobsis AC, De Vries GP, Meijer AE, et al. The immunohistochemical detection of prostatic acid phosphatase: Its possibilities and limitations in tumour histochemistry. Histochem J. 1981;13:961-973.
231. Kimura N, Sasano N, Namiki T. Evidence of hybrid cell of thyroid follicular cell and carcinoid cell in strumal carcinoid. Int J Gynecol Pathol. 1986;5:269-277.
232. Stagno PA, Petras RE, Hart WR. Strumal carcinoids of the ovary. An immunohistologic and ultrastructural study. Arch Pathol Lab Med. 1987;111:440-446.
233. Sidhu J, Sanchez RL. Prostatic acid phosphatase in strumal carcinoids of the ovary. An immunohistochemical study. Cancer. 1993;72:1673-1678.
234. Lundqvist M, Wilander E. Subepithelial neuroendocrine cells and carcinoid tumours of the human small intestine and appendix. A comparative immunohistochemical study with regard to serotonin, neuron-specific enolase and S-100 protein reactivity. J Pathol. 1986;148:141-147.
235. Moyana TN, Satkunam N. A comparative immunohistochemical study of jejunoileal and appendiceal carcinoids. Implications for histogenesis and pathogenesis. Cancer. 1992;70:1081-1088.
236. Barbareschi M, Frigo B, Mosca L, et al. Bronchial carcinoids with S-100 positive sustentacular cells. A comparative study with gastrointestinal carcinoids, pheochromocytomas and paragangliomas. Pathol Res Pract. 1990;186:212-222.
237. Tsuta K, Raso MG, Kalhor N, et al. Sox10-positive sustentacular cells in neuroendocrine carcinoma of the lung. Histopathology. 2011;58:276-285.
238. Al-Khafaji B, Noffsinger AE, Miller MA. Immunohistologic analysis of gastrointestinal and pulmonary carcinoid tumors. Hum Pathol. 1998;29:992-999.
239. Ko rner M, Waser B, Schonbrunn A, et al. Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol. 2012; 36:242-252.
240. Erickson JD, Schafer MK, Bonner TI, et al. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U. S. A. 1996; 93:5166-5171.
241. Rindi G, Paolotti D, Fiocca R, et al. Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors. Virchows Arch. 2000;436:217-223.
242. Anlauf M, Eissele R, Schafer MK, et al. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem. 2003;51:1027-1040.
243. Uccella S, Cerutti R, Vigetti D, et al. Histidine decarboxylase, DOPA decarboxylase, and vesicular monoamine transporter 2 expression in neuroendocrine tumors: Immunohistochemical study and gene expression analysis. J Histochem Cytochem. 2006;54:863-875.
244. Eissele R, Anlauf M, Schafer MK, et al. Expression of vesicular monoamine transporters in endocrine hyperplasia and endocrine tumors of the oxyntic stomach. Digestion. 1999;60:428-439.
245. Jakobsen AM, Andersson P, Saglik G, et al. Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours. J Pathol. 2001;195:463-472.
246. Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096-1100.
247. Shuda M, Feng H, Kwun HJ, et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci USA. 2008;105:16272-16277.
248. Garneski KM, Warcola AH, Feng Q, et al. Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J Invest Dermatol. 2009;129:246-248.
249. Shuda M, Arora R, Kwun HJ, et al. Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer. 2009;125:1243-1249.
250. Busam KJ, Jungbluth AA, Rekthman N, et al. Merkel cell polyomavirus expression in merkel cell carcinomas and its absence in combined tumors and pulmonary neuroendocrine carcinomas. Am J Surg Pathol. 2009;33:1378-1385.
251. Reisinger DM, Shiffer JD, Cognetta AB Jr, et al. Lack of evidence for basal or squamous cell carcinoma infection with Merkel cell polyomavirus in immunocompetent patients with Merkel cell carcinoma. J Am Acad Dermatol. 2010; 63:400-403.
252. Kuwamoto S, Higaki H, Kanai K, et al. Association of Merkel cell polyomavirus infection with morphologic differences in Merkel cell carcinoma. Hum Pathol. 2011;42:632-640.
253. Paik JY, Hall G, Clarkson A, et al. Immunohistochemistry for Merkel cell polyomavirus is highly specific but not sensitive for the diagnosis of Merkel cell carcinoma in the Australian population. Hum Pathol. 2011;42:1385-1390.
254. Jung HS, Choi YL, Choi JS, et al. Detection of Merkel cell polyomavirus in Merkel cell carcinomas and small cell carcinomas by PCR and immunohistochemistry. Histol Histopathol. 2011;26:1231-1241.
255. Ly TY, Walsh NM, Pasternak S. The spectrum of Merkel cell polyomavirus expression in Merkel cell carcinoma, in a variety of cutaneous neoplasms, and in neuroendocrine carcinomas from different anatomical sites. Hum Pathol. 2012;43:557-566.
256. Rodig SJ, Cheng J, Wardzala J, et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest. 2012;122:4645-4653.
257. Johansson L, Tennvall J, Akerman M. Immunohistochemical examination of 25 cases of Merkel cell carcinoma: A comparison with small cell carcinoma of the lung and oesophagus, and a review of the literature. APMIS. 1990;98: 741-752.
258. Shah IA, Netto D, Schlageter MO, et al. Neurofilament immunoreactivity in Merkel-cell tumors: A differentiating feature from small-cell carcinoma. Mod Pathol. 1993;6:3-9.
259. Lehto VP, Stenman S, Miettinen M, et al. Expression of a neural type of intermediate filament as a distinguishing feature between oat cell carcinoma and other lung cancers. Am J Pathol. 1983;110:113-118.
260. van Muijen GN, Ruiter DJ, van Leeuwen C, et al. Cytokeratin and neurofilament in lung carcinomas. Am J Pathol. 1984;116:363-369.
261. Shy SW, Lee WH, Chou MC, et al. Small cell lung carcinoma: Clinicopathological, immunohistochemical, and ultrastructural study. J Surg Oncol. 1990;45:146-161.
262. Gaffey MJ,Mills SE, Lack EE. Neuroendocrine carcinoma of the colon and rectum. A clinicopathologic, ultrastructural, and immunohistochemical study of 24 cases. Am J Surg Pathol. 1990;14:1010-1023.
263. Zamboni G, Franzin G, Bonetti F, et al. Small-cell neuroendocrine carcinoma of the ampullary region. A clinicopathologic, immunohistochemical, and ultrastructural study of three cases. Am J Surg Pathol. 1990;14:703-713.
264. Basturk O, Yang Z, Tang LH, et al. Increased (20%) Ki67 proliferation index in morphologically well differentiated pancreatic neuroendocrine tumors (PanNETs) correlates with decreased overall survival. Mod Pathol. 2013;26(suppl 2S):422A.